Q1 keeps Parnell on track for full-year forecast

摘要

Parnell Pharmaceuticals has recorded 9% growth in its first quarter of fiscal 2019.While this rate was down on the increase reported across 2018, Parnell said it remains on track to hit its provisional full-year 2019 guidance of 17-25% sales growth. Should the company reach this goal it would report annual turnover of Aus$31-$33m.These goals are subject to Parnell "winning at least one new contract manufacturing agreement", according to Brad McCarthy - Parnell's chief executive and executive director. The company is also targeting an EBITDA range of Aus$7.5-$8.5m in 2019.